Several DMD organizations recently teamed up to fund a Phase 2 clinical trial of a new therapy for Duchenne muscular dystrophy (DMD) – Carmeseal-MD. Carmeseal-MD…
Charley's Fund, Duchenne UK, and Joining Jack recently announced a collaborative grant to Dr. Dada Pisconti of the University of Liverpool in England. With this…
Harvard doctor and scientist Seward Rutkove recently published new data about Electrical Impedance Myography, a non-invasive outcome measure for Duchenne muscular dystrophy and other muscle diseases. Charley's…
The U.S. Food and Drug Administration today approved Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys…
It's taking a long time, but it's happening! Summit Therapeutics, a UK-based company we began supporting nine years ago, is making significant progress on its experimental…
Earlier this week at the annual PPMD Connect Conference in Orlando, Akashi Therapeutics CMO Dr. Diana Escolar presented an update on the HT-100 program. "We…
While we aggressively advocate for the approval of eteplirsen, we remain active on other medical research fronts. It's important to remember that eteplirsen helps 13%…
You probably already know that Charley's Fund is supporting the development of several new medicines to slow or halt Duchenne's deadly progression. Our goal is…